Compare SPFI & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | BIOA |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.2M | 681.9M |
| IPO Year | 2019 | N/A |
| Metric | SPFI | BIOA |
|---|---|---|
| Price | $42.62 | $24.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $46.00 | ★ $51.50 |
| AVG Volume (30 Days) | 161.4K | ★ 638.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | $720.93 |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $51.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $4.11 |
| 52 Week High | $45.09 | $25.80 |
| Indicator | SPFI | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 73.81 |
| Support Level | $38.32 | $15.42 |
| Resistance Level | $44.29 | N/A |
| Average True Range (ATR) | 1.15 | 1.67 |
| MACD | 0.18 | 0.48 |
| Stochastic Oscillator | 62.75 | 89.87 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.